【摘要】 目的研究PML－RARα在APL的特异性诊断、疗效判定等方面的作用。方法采用反转录聚合酶链反应技术（RT－PCR）检测了22例急性早幼粒细胞白血病（APL）患者的PML－RARα融合基因转录本。结果17例为初治患者，入院时检测均为阳性。13例经全反式维甲酸（ATRA）诱导分化治疗均达完全缓解（CR），缓解后检测融合基因转录本均为阳性。将13例患者随机分为MA方案组与HA方案组，化疗4次～5次后检测融合基因，4例转阴，MA方案组的融合基因转阴率（4／6）高于HA方案组（0／7）。结论APL经ATRA诱导缓解后化疗是必需的。MA方案疗效优于HA方案。更多还原

【Abstract】 Objective To study the clinic relevance of PML-RARa fusion gene was detected by reverse trdanscriptase polymeras chain react (RT-PCR) in acufe promyelocytic leukemia. Methods PML-RARαfusion gene was detected in 22 acute promylocytic leukemia (APL) patients by RT-PCR 17 cases before treatment all tested posted their chromosome, 4 cases showed normal karyotype,0nly l cases showed the karyotype t (15: 17). Results lt was th0ugh RT-PCR is more sensitive. 13 cases after the all-trans etinoic acid (ATRA) induced clinical remission (CR) remained positive chemotherapy consolidation coverted to negative. Conclusion It analyzed the negative results between MA (4/6) and HA (O/7), found MA is higher than HA (Pr0.025). Five of 22 patients in long-term remission (from 2 years to 8 after detection,died after three monthes. In 22 patients, 16 cases with L-type fusion gene (72.7% ), 6 cases with S-type fusion gene (27. 3% ). There are n0 defferent in age, sex and reaction th ATRA between the two type fusion gene (P>0. 55).更多还原